Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Intravitreal bevacizumab in central serous chorioretinopathy.

Jamil AZ, Rahman FU, Iqbal K, Ansari HM, Iqbal W, Mirza KA.

J Coll Physicians Surg Pak. 2012 Jun;22(6):363-6. doi: 06.2012/JCPSP.363366.

PMID:
22630094
2.

The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy.

Aydin E.

J Ocul Pharmacol Ther. 2013 Feb;29(1):10-3. doi: 10.1089/jop.2012.0072.

PMID:
22925113
3.

Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.

Seong HK, Bae JH, Kim ES, Han JR, Nam WH, Kim HK.

Ophthalmologica. 2009;223(5):343-7. doi: 10.1159/000224782.

4.

[Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].

Gregori-Gisbert I, Aguirre-Balsalobre F, García-Sánchez J, León-Salvatierra G, Mengual-Verdú E, Hueso-Abancéns JR.

Arch Soc Esp Oftalmol. 2011 Dec;86(12):407-11. doi: 10.1016/j.oftal.2011.05.021. Spanish.

PMID:
22117740
5.

Visual results following intravitreal Bevacizumab in neovascular age-related macular degeneration.

Iqbal K, Baig J, Jamil AZ, Jamil H, Mirza K, Khan T.

J Coll Physicians Surg Pak. 2011 Sep;21(9):535-8. doi: 09.2011/JCPSP.535538.

PMID:
21914409
6.

The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab.

Lee ST, Adelman RA.

J Ocul Pharmacol Ther. 2011 Dec;27(6):611-4. doi: 10.1089/jop.2011.0045.

PMID:
21810026
7.

Intravitreal bevacizumab injection for central serous chorioretinopathy.

Lim SJ, Roh MI, Kwon OW.

Retina. 2010 Jan;30(1):100-6. doi: 10.1097/IAE.0b013e3181bcf0b4.

PMID:
20010322
8.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S.

Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.

PMID:
21293319
9.

Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.

Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H.

Curr Eye Res. 2010 Feb;35(2):91-8. doi: 10.3109/02713680903428306.

PMID:
20136418
10.

Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.

Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S.

Eur J Ophthalmol. 2009 Jul-Aug;19(4):613-7.

PMID:
19551677
11.

Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.

Jonas JB, Tao Y, Schlichtenbrede FC.

J Ocul Pharmacol Ther. 2011 Oct;27(5):467-70. doi: 10.1089/jop.2011.0038.

PMID:
21682590
12.

The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.

Lim JW, Kim MU.

Graefes Arch Clin Exp Ophthalmol. 2011 Jul;249(7):969-74. doi: 10.1007/s00417-010-1581-9.

PMID:
21140161
13.

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group..

Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.

PMID:
18827735
14.

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.

Solaiman KA, Diab MM, Abo-Elenin M.

Retina. 2010 Nov-Dec;30(10):1638-45. doi: 10.1097/IAE.0b013e3181e1ed07.

PMID:
20838357
15.

Treatment of macular serous neuroretinal detachment in tilted disk syndrome: report of 3 cases.

Donati MC, Miele A, Abbruzzese G, Giuntoli M, Giansanti F, Menchini U.

Eur J Ophthalmol. 2013 Mar-Apr;23(2):267-70. doi: 10.5301/ejo.5000169.

PMID:
23225087
16.

Treatment of serous macular detachment associated with circumscribed choroidal hemangioma.

Kwon HJ, Kim M, Lee CS, Lee SC.

Am J Ophthalmol. 2012 Jul;154(1):137-145.e1. doi: 10.1016/j.ajo.2012.01.007.

PMID:
22465363
17.

[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].

Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.

J Fr Ophtalmol. 2011 Jun;34(6):376-81. doi: 10.1016/j.jfo.2011.03.004. French.

18.

Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.

Jonas JB, Tao Y, Rensch F.

J Ocul Pharmacol Ther. 2011 Aug;27(4):401-5. doi: 10.1089/jop.2011.0080.

PMID:
21810019
19.

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.

Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J, Rodríguez FJ; Pan-American Collaborative Retina Study Group (PACORES)..

Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):735-43. doi: 10.1007/s00417-008-1034-x.

PMID:
19189118
20.

Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.

Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU.

Retina. 2007 Feb;27(2):141-9.

PMID:
17290194

Supplemental Content

Support Center